Minerva Neurosciences, Inc. (NERV)
2.00
-0.12
(-5.66%)
USD |
NASDAQ |
Nov 20, 16:00
2.03
+0.03
(+1.50%)
After-Hours: 20:00
Minerva Neurosciences Research and Development Expense (TTM) : 19.77M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 19.77M |
| June 30, 2026 | 15.54M |
| March 31, 2026 | 9.652M |
| December 31, 2025 | 5.760M |
| September 30, 2025 | 5.569M |
| June 30, 2025 | 6.531M |
| March 31, 2025 | 9.094M |
| December 31, 2024 | 11.90M |
| September 30, 2024 | 14.64M |
| June 30, 2024 | 16.19M |
| March 31, 2024 | 14.22M |
| December 31, 2023 | 12.71M |
| September 30, 2023 | 11.17M |
| June 30, 2023 | 10.10M |
| March 31, 2023 | 12.34M |
| December 31, 2022 | 14.65M |
| September 30, 2022 | 30.21M |
| June 30, 2022 | 32.35M |
| March 31, 2022 | 33.74M |
| December 31, 2021 | 32.04M |
| September 30, 2021 | 16.84M |
| June 30, 2021 | 16.97M |
| March 31, 2021 | 17.22M |
| December 31, 2020 | 22.04M |
| September 30, 2020 | 28.01M |
| Date | Value |
|---|---|
| June 30, 2020 | 33.05M |
| March 31, 2020 | 35.60M |
| December 31, 2019 | 39.12M |
| September 30, 2019 | 38.61M |
| June 30, 2019 | 37.30M |
| March 31, 2019 | 38.05M |
| December 31, 2018 | 34.89M |
| September 30, 2018 | 32.42M |
| June 30, 2018 | 33.01M |
| March 31, 2018 | 31.09M |
| December 31, 2017 | 30.26M |
| September 30, 2017 | 30.21M |
| June 30, 2017 | 27.11M |
| March 31, 2017 | 22.68M |
| December 31, 2016 | 20.44M |
| September 30, 2016 | 20.20M |
| June 30, 2016 | 18.18M |
| March 31, 2016 | 19.95M |
| December 31, 2015 | 18.53M |
| September 30, 2015 | 15.24M |
| June 30, 2015 | 36.15M |
| March 31, 2015 | 46.22M |
| December 31, 2014 | 42.85M |
| September 30, 2014 | 40.04M |
| June 30, 2014 | 15.50M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Heron Therapeutics, Inc. | 11.93M |
| Tonix Pharmaceuticals Holding Corp. | 80.40M |
| Karyopharm Therapeutics, Inc. | 120.81M |
| Corbus Pharmaceuticals Holdings, Inc. | 103.65M |
| Ocugen, Inc. | 45.12M |